EMILY CRABTREE: Open Payments
NPI 1639525975 · LEBANON, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,207 in 61 payments from 14 companies in 2025. Trend: 2023 $1,011 · 2024 $1,206 · 2025 $1,207
Food & beverage: $1,207
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $307 |
| Neurocrine BioSciences, Inc. | 10 | $181 |
| ABBVIE INC. | 16 | $168 |
| Otsuka America Pharmaceutical, Inc. | 5 | $112 |
| Novo Nordisk Inc | 5 | $96 |
| GlaxoSmithKline, LLC. | 3 | $71 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $64 |
| Janssen Pharmaceuticals, Inc | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| PFIZER INC. | 2 | $35 |
Products named: INGREZZA, AIRSUPRA, REXULTI, BREZTRI, VRAYLAR, TRELEGY ELLIPTA, FARXIGA, CAPLYTA.
Industry payments across VA — which companies pay providers there.
